Targeting platelet thrombin receptor signaling to prevent thrombosis

Eric L. Wallace, Susan S. Smyth

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Platelets contribute fundamentally to ischemic heart disease, and antiplatelet therapy has been critical to reducing acute thrombotic complications of atherosclerotic disease. Thrombin, by acting on protease activated receptors (PAR), is one of the most potent platelet activators. PAR-1 antagonists may therefore provide more comprehensive antithrombotic effects. We review the pathophysiology of atherothrombosis, platelet activation by thrombin, the role of platelet protease activated receptors (PAR), and the clinical data supporting their use.

Original languageEnglish
Pages (from-to)915-928
Number of pages14
Issue number8
StatePublished - Feb 8 2013


  • Platelets
  • Protease-activated receptors
  • Thrombin
  • Thrombosis

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery


Dive into the research topics of 'Targeting platelet thrombin receptor signaling to prevent thrombosis'. Together they form a unique fingerprint.

Cite this